Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 5/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221460 | 0.78 | KMT2A (0.40) | MAPKAPK2MEN1KMT2ATAAR1PTGDR2 | |
| SCHEMBL7220960 | 0.77 | MEN1 (0.35) | MEN1KMT2ATAAR1PTGDR2SLC6A9 | |
| SCHEMBL7221098 | 0.72 | TAAR1 (0.39) | MAPKAPK2MEN1KMT2ATAAR1CYP3A4 | |
| SCHEMBL7216749 | 0.72 | LOXL2 (0.38) | MAPKAPK2CYP19A1MAPK14 | |
| SCHEMBL7221128 | 0.72 | MEN1 (0.36) | MAPKAPK2MEN1KMT2ATAAR1SLC6A9 | |
| SCHEMBL7221014 | 0.72 | KCNH3 (0.40) | MEN1KMT2A | |
| SCHEMBL2789136 | 0.70 | LTA4H (0.42) | MAPKAPK2MEN1KMT2ATAAR1CYP19A1 | |
| SCHEMBL7220974 | 0.70 | DPP4 (0.38) | MAPKAPK2TAAR1CYP19A1MAPK14 | |
| SCHEMBL7214541 | 0.68 | USP2 (0.39) | MAPKAPK2MEN1KMT2ATAAR1CYP19A1 | |
| SCHEMBL7216865 | 0.66 | ACHE (0.43) | MEN1KMT2ACYP3A4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |